1104546-31-7Relevant academic research and scientific papers
COMPOSITIONS OF CHOLINESTERASE INHIBITORS
-
Page/Page column 15, (2010/10/19)
The present invention is directed to compositions, methods of use, and processes for the synthesis related to 3-((S)-1-(dimethylamino)ethyl)phenyl methyl-((R)-1-phenylpropan-2 yl)carbamate, and its pharmaceutically acceptable salt forms, including the hydrogen fumarate salt. The present invention also relates to a novel form polymorph of 3-((S)-1-(dimethylamino)ethyl)phenylmethyl-((R)-1-phenylpropan-2 yl)carbamate, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition
Verheijen, Jeroen C.,Wiig, Kjesten A.,Du, Shoucheng,Connors, Stacie L.,Martin, Ashley N.,Ferreira, Jennifer P.,Slepnev, Vladimir I.,Kochendoerfer, Ulrike
scheme or table, p. 3243 - 3246 (2010/08/06)
Conjugation of the phenol derived from rivastigmine with amphetamines gave access to novel carbamate cholinesterase inhibitors. All compounds possessed increased affinity and selectivity for AChE compared to rivastigmine and were orally bioavailable. Comp
